Ignite Creation Date:
2024-05-06 @ 10:01 AM
Last Modification Date:
2024-10-26 @ 12:23 PM
Study NCT ID:
NCT03130582
Status:
COMPLETED
Last Update Posted:
2017-04-28
First Post:
2017-04-22
Brief Title:
High-dose Etoposide Could Discriminate Patients With RefractoryRelapsed Lymphoma Benefit From APBSCT
Sponsor:
Yang Jun
Organization:
Shanghai General Hospital Shanghai Jiao Tong University School of Medicine
Study Overview
Official Title:
2008 WHO Myeloid and Lymphocytic Tumor Diagnostic Criteria
Status:
COMPLETED
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
patients with refractory relapsed lymphoma received high-dose etoposide for hematopoietic stem cell HSC mobilizationAll patients received high-dose etoposide 20-25 mgkgd intravenously for two consecutive days followed by rhG-CSF10ugkgday subcutaneously at 48 hours after chemotherapy rhG-CSF was continued until the end of harvesting for HSCsHPCs Peripheral blood counts were performed daily for all patients following the initiating of rhG-CSF Leukapheresis was performed when peripheral blood white blood count exceeded 4109L with blood cell The harvested cells reached at least 2108kg for mononuclear cells andor 2106kg for CD34 cells with once to twice leukapheresis The final product was kept frozen in liquid nitrogenAuto-PBSCT
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None